Resources

Will U.S. Doctors Prescribe Biosimilars?
By Charu Gupta

A new InCrowd MicroSyndicated Survey Report looks at what 150 physicians across multiple specialty areas commonly requiring prescription of biologics think about the coming market in biosimilars.

Our survey, administered using our real-time microsurvey technology platform, probes the intersections between market evolution and patient needs. See our infographic below for a summary of some of the key findings, and please contact us at syndicated@incrowdnow.com to get a complimentary copy of the full report that includes doctor perspectives by specialty area.

 

 

Related Resources

See the MM&M article about RSV tracking

See the MM&M article about RSV tracking

“Coming so early in the flu and respiratory illness season, and before the holidays, the data suggests it may be a very challenging winter. We will continue to track the voice of clinicians as an important barometer for U.S. healthcare resources,” Daniel S....

read more
HCP Perspective on Amazon Care

HCP Perspective on Amazon Care

In September InCrowd surveyed attending physicians, nurses, medical residents and fellows on their thoughts about Amazon Care.  Amazon Care was first launched in 2019 with the hopes of providing 24/7 telehealth services and in-person care to customers in the US....

read more
Employee Spotlight: Molly Simpson

Employee Spotlight: Molly Simpson

What is your role within InCrowd? Marketing Director, InCrowd, Inc. What interested you when deciding to join InCrowd? I've worked for InCrowd for almost nine years so it's been a long time since I thought about this. I remember being really excited about the new...

read more